Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study

Seitz, M; Reichenbach, S; Möller, B; Zwahlen, M; Villiger, PM; Dufour, Jean-François (2010). Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Annals of the rheumatic diseases, 69(6), pp. 1148-1150. London: BMJ Publishing Group 10.1136/ard.2009.116194

[img] Text
Seitz AnnRheumDis 2010.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Download (85kB) | Request a copy
[img]
Preview
 Text
Seitz AnnRheumDis 2009.pdf - Accepted Version
Available under License Publisher holds Copyright.
Download (83kB) | Preview

Objective To evaluate the impact of tumour necrosis factor α (TNFα) blockers on the presence of liver fibrosis in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with methotrexate (MTX).

Methods Participants were consecutive patients with RA and PsA who had undergone MTX treatment for at least 1 year ± TNF blockade for over 6 months. Liver fibrosis was assessed using non-invasive transient elastography (FibroScan). Regression models were used to compare FibroScan values of patients with RA and patients with PsA receiving TNFα blockers with those who were not.

Results FibroScan assessments were performed on 51 patients with RA and 43 patients with PsA. Compared to patients with RA, those with PsA were predominantly young men, received lower cumulative dosages of MTX and exhibited a higher incidence of liver steatosis and hyperlipidaemia. An abnormal result was observed in 7.1% of the anti-TNFα-naïve and in 13% of the anti-TNFα-treated patients in the RA group and in 30% of the anti-TNFα-naïve and 4.3% of the anti-TNFα-treated patients in the PsA group (OR=0.11, 95% CI 0.02 to 0.98). Results of the PsA group were robust when adjusted for baseline characteristics.

Conclusion The results suggest a protective effect of TNFα inhibitors against the development of liver fibrosis in patients with PsA.

Item Type:

 Journal Article (Original Article)

Division/Institute:

 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Service Sector > Institute of Clinical Pharmacology and Visceral Research [discontinued]
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

 Seitz, Michael, Reichenbach, Stephan, Möller, Burkhard, Zwahlen, Marcel, Villiger, Peter Matthias, Dufour, Jean-François

Subjects:

 600 Technology > 610 Medicine & health

ISSN:

 0003-4967

Publisher:

 BMJ Publishing Group

Language:

 English

Submitter:

 Factscience Import

Date Deposited:

 04 Oct 2013 14:07

Last Modified:

 05 Dec 2022 14:00

Publisher DOI:

 10.1136/ard.2009.116194

PubMed ID:

 19854710

Web of Science ID:

 000278017700036

BORIS DOI:

 10.7892/boris.116

URI:

 https://boris.unibe.ch/id/eprint/116 (FactScience: 196164)

Actions (login required)

Edit item Edit item
Provide Feedback